Boehringer Ingelheim GmbH has signed an option to acquire partner Trutino Biosciences, Inc. for its next-generation ‘on-demand’ cytokine platform, marking its second deal this month aimed at bulking up its oncology pipeline.
Boehringer has retained the right to buy all shares of Trutino upon the completion of certain program milestones within a given timeframe and the target will continue to operate as an independent firm in the meantime. The transaction will include an option fee, the issuance of a convertible note and fixed purchase price terms
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?